anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises stannonium compounds of formula [RmSn(Am)y]X4-m, wherein R is an aliphatic, aromatic or heterocyclic group which may be substituted, m is 2 or 3, Am is amine or heterocyclic base, y is 1 or 2 and X is halogen, or a residue of a carboxylic acid, an ester thereof, a mercaptoacid, an ester thereof, an arylsulphonic acid, a sulphonamide, a dithiocarbamate, an isodithiocarbamate or a xanthate, or an ORa or SRa group wherein Ra is a hydrocarbon group which may be substituted.  They may be prepared by reacting an organotin compound of formula R2SnX2 or R3SnX with the amine or base.  R may be an alkyl, alkenyl, alkaryl or aralkyl group having up to 22 carbon atoms in the open chain. Specified amines and bases include octyl amine, lauryl amine, stearyl amine, oleyl amine, cyclohexylamine, benzyl amine, aniline, p-phenylene diamine, dioctyl amine, dicetylamine, dilauryl amine, dodecylmethyl amine, dicyclohexyl amine, methyl aniline, piperidine, morpholine, piperazine, phenothiazine, tripropyl amine, dimethyl benzyl amine, trilauryl amine, pyridine, dimethyl lauryl amine, dimethyl aniline, methyldicyclohexylamine, quinoline, 8-hydroxy-quinoline, glyceryl diethylamine, cyclohexyldiethylamine. Specified X groups include butoxy, lauroxy, phenoxy and the sulphur analogues, and the residues of the following: acetic, lactic, stearic, maleic, fumaric, citric, phthalic, benzoic and a -mercaptolauric acids, mercaptoethanol, iso-octylmercaptoacetoate and laurylmercaptan.  The compounds are anthelmintics (see Group VI). The preparation of bis-(piperazino)-dibutylstannonium dilaurate by mixing piperazine with dibutyltin dilaurate is described. Specifications 814,064 and 815,819 are referred to.ALSO:An anthelmintic composition for oral ingestion by fowls contains a compound of formula [RmSn(Am)y]X4-m, wherein R is an aliphatic, aromatic or heterocyclic group which may be substituted, m is 2 or 3, Am is amine or heterocyclic base, y is 1 or 2 and X is halogen, or an ORa or SRa group wherein Ra is a hydrocarbon group which may be substituted, or a residue of a carboxylic acid, an ester thereof, a mercaptoacid, an ester thereof, an arylsulphonic acid, a sulphonamide, a dithiocarbamate, an isodithiocarbamate or a xanthate.  Preferably, Am in the above formula is piperazine, phenothiazine, dilaurylamine, X is chlorine, laurate, acetate and y is 2.  Where Am and X comply with these requirements R may conveniently be butyl, phenyl, octyl. Where R is butyl m may be 2 or 3, where R is phenyl m may be 3, where R is octyl m may be 2.  Specifications 814,064 and 815,819, [both in Group IV (b)], are referred to.
FIELD: medicine, pharmacy. SUBSTANCE: preparation has morphine as a pharmaceutically acceptable water-soluble salt in combination with a buffer agent. Preparation is covered by diffusion membrane made of water-insoluble and gastroenteric fluid-insoluble triple copolymer containing links of vinyl chloride, vinyl acetate and vinyl alcohol. Pore-forming water-soluble agent is dispersed in copolymer which is taken at amount 1-20 mas. p. per 1-10 mas. p. triple copolymer. Diffusion membrane provides pH-independent release of morphine in vitro for at least 8 h at amount less 100 and above 50% of total morphine dose. Plasma blood morphine effective level is obtained for at least 24 h. Preparation provides practically complete biological availability of morphine and can be used in cancer therapy for pains relief. EFFECT: enhanced effectiveness of preparation. 8 cl, 3 tbl, 1 dwg
Streptococcus suis type 2 (SS2) is a zoonotic pathogen capable of eliciting meningitis, presenting significant challenges to both the swine industry and public health. Suilysin (Sly), one of SS2 most potent virulence determinants, releases a surfeit of inflammatory agents following red blood cell lysis. Notably, while current research on Sly role in SS2-induced meningitis predominantly centers on its interaction with the blood-brain barrier (BBB), the repercussions of Sly hemolytic products on BBB function have largely been sidestepped. In this vein, our study delves into the ramifications of Sly-induced hemolysis on BBB integrity. We discern that Sly hemolytic derivatives exacerbate the permeability of Sly-induced in vitro BBB models. Within these Sly hemolytic products, Interleukin-33 (IL-33) disrupts the expression and distribution of Claudin-5 in brain microvascular endothelial cells, facilitating the release of Interleukin-6 (IL-6) and Interleukin-8 (IL-8), thereby amplifying BBB permeability. Preliminary mechanistic insights suggest that IL-33-driven expression of IL-6 and IL-8 is orchestrated by the p38-mitogen-activated protein kinase signaling, whereas matrix metalloproteinase 9 mediates IL-33-induced suppression of Claudin-5. To validate these in vitro findings, an SS2-infected mouse model was established, and upon intravenous administration of growth stimulation expressed gene 2 (ST2) antibodies, in vivo results further underscored the pivotal role of the IL-33/ST2 axis during SS2 cerebral invasion. In summation, this study pioneerly illuminates the involvement of Sly hemolytic products in SS2-mediated BBB compromise and spotlights the instrumental role and primary mechanism of IL-33 therein. These insights enrich our comprehension of SS2 meningitis pathogenesis, laying pivotal groundwork for therapeutic advancements against SS2-induced meningitis.IMPORTANCEThe treatment of meningitis caused by Streptococcus suis type 2 (SS2) has always been a clinical challenge. Elucidating the molecular mechanisms by which SS2 breaches the blood-brain barrier (BBB) is crucial for the development of meningitis therapeutics. Suilysin (Sly) is one of the most important virulence factors of SS2, which can quickly lyse red blood cells and release large amounts of damage-associated molecular patterns, such as hemoglobin, IL-33, cyclophilin A, and so on. However, the impact of these hemolytic products on the function of BBB is unknown and ignored. This study is the first to investigate the effect of Sly hemolytic products on BBB function. The data are crucial for the study of the pathogenesis of SS2 meningitis and can provide an important reference for the development of meningitis therapeutics.
PROBLEM TO BE SOLVED: To obtain a sebum suppressing agent exhibiting a specific sebum secretion-suppressing effect and not causing adverse effect without affecting influence on other organs by using a specific compound capable of readily synthesizing as an active ingredient. SOLUTION: This sebum suppressing agent is obtained by using tranexamic acid methyl amide and/or its salt. A blend amount of the active ingredient is preferably 0.001-20wt.%, more preferably 0.01-7wt.%. Tranexamic acid methyl amide or its salt is obtained by protecting an amino group of tranexamic acid with a proper protecting group, e.g. benzyloxycarbonyl group, etc., reacting the protected body or its reactive derivative with methylamine gas, liquefied methylamine, etc., and eliminating a protective group. For example, N-methyl- trans-4-aminomethylcyclohexanecarboxylic amide, etc., can be exemplified as the active ingredient.
Menopause is accompanied by a variety of physiological changes and symptoms, including hot flashes, nightly sweating, anxiety, headaches, vaginal dryness, lethargy, irritability, and sleep disturbance. Menopause and its symptoms frequently have an impact on postmenopausal women's quality of life, a metric that is influenced by a variety of societal and personal circumstances. The Menopause-Specific Quality of Life Questionnaire(MENQOL) evaluates the prevalence and severity of bothersome physical and psychological concerns that women could experience during the menopausal transition.

As cross-border and cross-cultural studies continue to increase, there is a greater need for linguistic validation of tools in various societies. Until now no translation or adaptation of the MENQOL questionnaire has been made for the population with different languages in Pakistan. There is a need for culturally adapted screening tools to aid healthcare professionals or clinicians to screen the symptoms of menopausal women in the Pakistani population. As the Urdu language is Pakistan's national language so commonly used all over Pakistan, so it is required to translate and culturally adapt the MENQOL scale into Urdu language for the Pakistani population.
The action of Corepressor for Element Silencing Transcription Factor 1 (CoREST) is primarily related to neural fate decisions. However, the molecular mechanisms linking neuroinflammation to the histone modifying complex remain unclear. CoREST is a hub for several cofactors that play important roles in epigenetic remodeling and transcriptional regulation. It allows us to question their functions during the inflammatory response in the Central Nervous System. The impact of LPS-induced neuroinflammation on the transcriptional epigenetic control of members with CoRest repressive complex in the hippocampus was investigated. Characterizing the basal transcriptional profile in the hippocampus of members with CoREST repressive complex showed that the Rcor3 is the most expressed gene, and the Rcor2 is the least expressed one. It was also demonstrated that the levels of Lsd1, CoREST1 (Rcor1), and CoREST2 (Rcor2) transcripts increased in the hippocampus after LPS i.p. administration, while for CoREST3 (Rcor3), no significant difference was observed. A significant increase was noticed in the percentages of the 5-meC mark (Hypermethylation) for the Rcor1 and Lsd1 genes with a positive Pearson correlation between methylation and expression. However, the correlation was directly proportional, ruling out DNA methylation as the main mechanism in transcriptional control.
Lerapolturev (up to 1.6x10\^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 or 4 weeks thereafter. Anti-PD-1 therapy given as per the anti-PD-1 approved package insert.
Agonists targeting the receptors of incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, have been well established for the treatment of type 2 diabetes mellitus. There is increasing awareness that gastroenterologists and hepatologists should be treating obesity when patients present to their clinics. In addition, gastroenterologists and hepatologists should be aware of the effects of these classes of medications prescribed by other providers. Therefore, given the widespread use of incretin agonists for obesity treatment and weight loss, it is important to recognize their effects in the gastrointestinal tract, which could constitute significant benefits in weight loss and cardiometabolic benefits, but can be associated with adverse effects that constitute a potential barrier to their use, particularly at higher doses. Multiple studies reviewed in this article document the diverse effects of these drugs on the glucagon-like peptide-1 receptors that are widely expressed in the human body, including the nervous system modulating appetite, the gastrointestinal tract modifying gastric emptying, and lipid metabolism regulation leading to reduction in fat deposition. The objective of this review is to summarize the mechanism of action of incretin receptor agonists, their effects in the gastrointestinal tract, and implications in clinical practice, particularly in the practice of gastroenterology, endoscopy, and surgery.
Video narratives will be provided by Latino community health workers, known as Promotores de Salud (PdS), who will wear and experience the continuous glucose monitoring (CGM) system and its glycemic variability feedback. In Study 1 (G1), the investigator will conduct a Phase 0 intervention development study, enrolling a sample of 20 Spanish- and/or English-speaking PdS who test positive for pre-diabetes via a finger prick screening. Participants will wear CGM devices for 20 days, during which they will record daily narratives about their experiences with the CGM feedback and their glucose variability. Structured interviews between staff and participants will explore the benefits and barriers of CGM use. These recorded video clips will serve as the foundation for educational cinematic smartphone videos for future interventions. The investigator will then use artificial intelligence tools to translate the text, audio, and video clips into various languages for broad dissemination. Blood glucose levels in mg/dL will be recorded continuously over the wear period.
PCT No. PCT/JP94/01187 Sec. 371 Date Jan. 18, 1996 Sec. 102(e) Date Jan. 18, 1996 PCT Filed Jul. 19, 1994 PCT Pub. No. WO95/03056 PCT Pub. Date Feb. 2, 1995A hepatitis C virus proliferation inhibitor comprising a bile acid or a physiologically acceptable salt thereof is disclosed, as well as a method for treating a mammal infected with hepatitis C and a pharmaceutical composition for treating hepatitis C. As the bile acid to be used in the present invention, free bile acids, such as ursodeoxycholic acid and chenodeoxycholic acid, and conjugated bile acids such as tauroursodeoxycholic acid are exemplified. Also, as the physiologically acceptable salt, alkali metal salts such as the sodium salt of the bile acid is exemplified.
The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies )]. The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies [see Warnings and Precautions ( 5.1)]. 

Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support [See Clinical Studies ( 14.3)] . 

Kepivance is not recommended for use with melphalan 200 mg/m as a conditioning regimen. Kepivance is not recommended for use with melphalan 200 mg/m 2 as a conditioning regimen [See Clinical Studies ( 14.2)] .
Thrombotic/thromboembolic complications may result from increases in platelet counts with PROMACTA. Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.

Consider the potential for an increased risk of thromboembolism when administering PROMACTA to patients with known risk factors for thromboembolism (e.g., Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease). To minimize the risk for thrombotic/thromboembolic complications, do not use PROMACTA in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain target platelet counts [see Dosage and Administration (2.1, 2.2, 2.3)].

In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, 3% (31/955) treated with PROMACTA experienced a thrombotic event compared with 1% (5/484) on placebo. The majority of events were of the portal venous system (1% in patients treated with PROMACTA versus less than 1% for placebo).

In a controlled trial in patients with chronic liver disease and thrombocytopenia not related to ITP undergoing elective invasive procedures (N = 292), the risk of thrombotic events was increased in patients treated with 75 mg of PROMACTA once daily. Seven thrombotic complications (six patients) were reported in the group that received PROMACTA and three thrombotic complications were reported in the placebo group (two patients). All of the thrombotic complications reported in the group that received PROMACTA were portal vein thrombosis (PVT). Symptoms of PVT included abdominal pain, nausea, vomiting, and diarrhea. Five of the six patients in the group that received PROMACTA experienced a thrombotic complication within 30 days of completing treatment with PROMACTA and at a platelet count above 200 x 109/L. The risk of portal venous thrombosis was increased in thrombocytopenic patients with chronic liver disease treated with 75 mg of PROMACTA once daily for 2 weeks in preparation for invasive procedures.
BACKGROUND: In familial adenomatous polyposis (FAP) patients, fundic gland polyps (FGPs) have been considered a risk factor for gastric neoplasms. We speculated that FGPs in FAP patients spread directionally from the greater to the lesser curvature of the gastric body and investigated the relationship between the distribution of FGPs and gastric neoplasm development.
METHODS: We extracted 195 FAP patients from two institutions and reviewed their medical records. Gastric polyposis was classified based on the FGP distribution (P0, no FGPs; P1, localized in the fundus or greater curvature of the gastric body; P2, spreading to the anterior or posterior wall; P3, involving the proximal half of the lesser curvature; and P4, spreading from P3 to the anal side of the lesser curvature).
RESULTS: The 195 eligible patients were divided into the neoplasm group (n = 54, 28%) and the non-neoplasm group (n = 141, 72%). Overall, 24% of the patients were Helicobacter pylori (H. pylori)-positive. In the FGP distribution, the rate of patients with gastric neoplasm tended to increase significantly with each step towards an increasingly wide distribution from P0 to P4 in H. pylori-negative patients, but not in H. pylori-positive ones. In addition, in H. pylori-negative patients, the likelihood of neoplasm increased consistently from P0 to P4, with the highest odds ratio (95% confidence interval) at P4 of 14.1 (2.5-154.4). Furthermore, multivariate analysis showed P4 and Spigelman stage ≥III were significantly associated with gastric neoplasm development.
CONCLUSION: FGP distribution was correlated with gastric neoplasm development in FAP patients.
PCT No. PCT/FR96/01790 Sec. 371 Date Jul. 31, 1998 Sec. 102(e) Date Jul. 31, 1998 PCT Filed Nov. 13, 1996 PCT Pub. No. WO97/18317 PCT Pub. Date May 22, 1997A native or recombinant adenoviral protein complex, a pharmaceutical composition containing said protein complex, and the uses thereof for treating and preventing human and animal diseases, are disclosed. Said adenoviral protein complex consists of either 12 pentons each including at least one fiber and a penton base, but no other element from an adenovirus genome, said fiber(s) and said penton base being derived from one or more adenoviruses, said pentons being bound by the penton bases and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 4.8x106 and 6.6x106, and such complexes being known as dodecahedron-penton complexes; or 12 penton bases but no other element from an adenovirus genome, said penton bases being derived from one or more adenoviruses and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 3.2x106 and 4x106, and such complexes being known as dodecahedron-base complexes.
This study examined day-level associations between trouble sleeping and three cannabis-use indices (likelihood/quantity of use and impaired control). We evaluated behavioral and cognitive mediators of the association between trouble sleeping and cannabis outcomes. Youth (N = 86, ages 15-24, 48.8% female, 58.8% White, 18.6% Latine) who regularly used cannabis were recruited for an intervention study. This preregistered secondary data analysis leveraged data from a 1-week ecological momentary assessment (EMA) study completed prior to intervention. Trouble sleeping, cannabis use, and impaired control over use were assessed each morning; negative affect, risk-taking propensity, and cannabis craving were assessed multiple times and aggregated to create a daily average. Multilevel structural equation modeling evaluated hypothesized temporally sequenced associations and putative mechanisms at the day (i.e., within) and person (i.e., between) level. In bivariate analyses at the person level, there were large-effect associations between trouble sleeping and craving and negative affect, and between craving and cannabis-use likelihood and quantity (rs from .34 to .48). In multilevel analyses at the day level, participants were less likely to use cannabis the next day after reporting more trouble sleeping (β = -.65, p < .001). Trouble sleeping was not directly associated with subsequent cannabis-use quantity or impaired control, or indirectly via negative affect, risk-taking propensity, or craving. Trouble sleeping had differential relations with cannabis-use indices at the day and person levels. To promote youth health and reduce cannabis use, future research may consider the unique, person- and situation-driven mechanistic processes at play. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
In this group patients will be treated with PT treatment with balance training. Exercises for stability of posture on numerous surfaces and positions were performed by Group B, including exercises for the flexors and adductors of hip, flexors and extensors of knee, and calf muscle (15-second hold and five repetitions) for improving their flexibility. The lower extremity and trunk muscles were the focus of Group B. The postural control exercise included walking in every direction, moving past the point of stability in various postures like half-kneeling, standing on hard and soft surfaces, stepping down and up, walking and standing at the same time, and one leg standing with eyes open and closed. Each session started with a 5-minute warm-up and ended with a 5-minute cool-down in between each phase.
Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
Placebo for the first 12 weeks and ustekinumab for the following 40 weeks. The dose will be determined by the participant's body weight.
In Phase 3 clinical trials, a total of 564 patients were treated with CIPRO® HC OTIC. Adverse events with at least remote relationship to treatment included headache (1.2%) and pruritus (0.4%). The following treatment-related adverse events were each reported in a single patient: migraine, hypesthesia, paresthesia, fungal dermatitis, cough, rash, urticaria, and alopecia.

The following reactions have been identified during post-approval use of CIPRO® HC OTIC in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to CIPRO® HC OTIC, or a combination of these factors, include: dizziness, ear canal erythema, ear congestion, hypoacusis and medication residue.